Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

References

• Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85–94
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122–9
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia: 1991. Soc Psychiatr Epidemiol 1995;30:196–205
   PubMed Web of Science ®Google Scholar
• Rice DP. The economic impact of schizophrenia. J Clin Psychiatry 1999;60(Suppl 1):4–6
   PubMedGoogle Scholar
• Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14:105–22
   PubMedGoogle Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419–29
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637–51
   Google Scholar
• Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173–88
   PubMed Web of Science ®Google Scholar
• Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005;22:319–62
   Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196–201
   PubMed Web of Science ®Google Scholar
• Magura S, Laudet AB, Mahmood D, et al. Adherence to medication regimens and participation in dual-focus self-help groups. Psychiatr Serv 2002;53:310–16
   PubMed Web of Science ®Google Scholar
• Berger BA, Krueger KP, Felkey BG. The pharmacist’s role in treatment adherence. Part 1: Extent of the problem. US Pharmacist 2004;29: 50–4
   Google Scholar
• Schoen MD, DiDomenico RJ, Connor SE, et al. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy 2001;21:1455–63
   PubMed Web of Science ®Google Scholar
• Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc 1998;38:574–85
   Google Scholar
• Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995;152:1749–56
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenia patients. J Nerv Ment Dis 1984;172:412–16
   Google Scholar
• Caton CLM, Koh SP, Fleiss JL, et al. Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 1985;173:139–48
   PubMed Web of Science ®Google Scholar
• Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry 1988;39:963–6
   PubMedGoogle Scholar
• Casper ES, Regan JR. Reasons for admission among six profile subgroups of recidivists of inpatient services. Can J Psychiatry 1993;38:657–61
   PubMed Web of Science ®Google Scholar
• Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the ‘revolving door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;2:856–61
   Google Scholar
• Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the post-institutional era in the US. Pharmaco-economics 1995;8:199–222
   Google Scholar
• Delaney C. Reducing recidivism: medication vs psychological rehabilitation. J Psychosocial Nursing 1998;36:28–34
   PubMedGoogle Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216–22
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630–9
   PubMed Web of Science ®Google Scholar
• Al-Zakwani IS, Barron JJ, Bullano MF, et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003;19:619–26
   Google Scholar
• Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509–16
   PubMed Web of Science ®Google Scholar
• Rittmannsberger H, Pachinger T, Keppelmüller P, et al. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 2004;55:174–9
   Google Scholar
• Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27:263–72
   Google Scholar
• Kelly GR, Scott JE, Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990;28:1181–97
   Google Scholar
• Corriss DJ, Smith TE, Hull JW, et al. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res 1999;89:269–74
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886–91
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medical regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990;2:19–33
   Google Scholar
• Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989;27:1159–66
   PubMed Web of Science ®Google Scholar
• Skaer TL, Sclar DA, Robinson LM. Noncompliance with anti hypertensive therapy. Economic consequences. Pharmaco-economics 1996;9:1–4
   Google Scholar
• Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10(Pt 2):144–51
   Google Scholar
• Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmaco-economics 2000;18:106–24
   PubMedGoogle Scholar
• Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54:508–16
   PubMed Web of Science ®Google Scholar
• National and regional estimates on hospital use for all patients from the HCUP Nationwide Inpatient Sample (NIS). Available at http://hcupnet.ahrq.gov/HCUPnet.jsp?Id=4BF191B03CAE83A4&Form=SelLAY&JS=Y&Action=%3E%3ENext%3E%3E&_LAY=Researcher [Last accessed June 23, 2007]
   Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805–11
   Google Scholar
• Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in ‘revolving door’ schizophrenic patients. J Clin Psychiatry 1996;57:337–45
   PubMed Web of Science ®Google Scholar
• Harman JS, Manning WG, Lurie N, et al. Association between interruptions in Medicaid coverage and use of inpatient psychiatric services. Psychiatr Serv 2003;54:999–1005
   PubMed Web of Science ®Google Scholar
• Mortimer A, Williams P, Meddis D. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost. J Int Med Res 2003;31:188–96
   Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692–9
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163: 611–22
   PubMed Web of Science ®Google Scholar
• Mullins CD, Obeidat NA, Cuffel BJ, et al. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res. 2007 Jun 25 [Epub ahead of print]
   Google Scholar